These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7754928)

  • 41. [Clinical application of beta-lactamase inhibitors on urinary tract infections].
    Ohkawa M
    Nihon Rinsho; 1986 Dec; 44(12):2573-7. PubMed ID: 3029463
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
    Jacobs MR; Aronoff SC; Johenning S; Yamabe S
    J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections.
    Aldridge KE
    Am J Surg; 1995 May; 169(5A Suppl):2S-7S. PubMed ID: 7755163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Beta-lactamases with a wide substrate spectrum in gram negative strictly anaerobic rods].
    Rokosz A; Sawicka-Grzelak A; Kot K; Pituch H; Meisel-Mikołajczyk F; Luczak M
    Med Dosw Mikrobiol; 2000; 52(2):129-37. PubMed ID: 11107787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical evaluation of Augpenin (clavulanic acid-ticarcillin) in urinary tract infections: especially against beta-lactamase producing strains].
    Shiono A; Kurihara J; Hayashi M; Suzuki T; Imai K; Yamanaka H; Takezawa Y; Kiren H; Okabe K; Tomaru Y
    Hinyokika Kiyo; 1993 Aug; 39(8):777-82. PubMed ID: 8379483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beta-lactamase inhibition: therapeutic advances. Proceedings of a symposium. Fort Lauderdale, Florida, March 22-23, 1985.
    Am J Med; 1985 Nov; 79(5B):1-196. PubMed ID: 3878079
    [No Abstract]   [Full Text] [Related]  

  • 48. Emerging trends in antimicrobial resistance in surgical infections. A review.
    Neu HC
    Eur J Surg Suppl; 1994; (573):7-18. PubMed ID: 7524800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The incidence of beta-lactamase-producing pathogens.
    Acar JF; Kitzis MD; Gutmann L
    APMIS Suppl; 1989; 5():2-8. PubMed ID: 2660867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of ticarcillin and ticarcillin/clavulanic acid on the in-vitro activity of human granulocytes against beta-lactamase-producing Klebsiella pneumoniae.
    Cuffini AM; de Renzi G; Tullio V; Paizis G; Carlone NA
    Int J Tissue React; 1995; 17(5-6):199-203. PubMed ID: 8835630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections.
    McKinnon PS; Neuhauser MM
    Pharmacotherapy; 1999 Jun; 19(6):724-33. PubMed ID: 10391418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-lactamase inhibitors from laboratory to clinic.
    Bush K
    Clin Microbiol Rev; 1988 Jan; 1(1):109-23. PubMed ID: 3060240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ticarcillin disodium/clavulanate potassium versus clindamycin/gentamicin in the treatment of postpartum endometritis.
    Faro S; Martens M; Phillips LE; Hamill H; Smith D; Riddle G
    J Reprod Med; 1988 Jun; 33(6 Suppl):603-6. PubMed ID: 3294407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anaerobes in polymicrobial surgical infections: incidence, pathogenicity, and antimicrobial resistance.
    Aldridge KE
    Eur J Surg Suppl; 1994; (573):31-7. PubMed ID: 7524793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beta-lactamase inhibitors: another approach to overcoming antimicrobial resistance.
    Parker RH; Eggleston M
    Infect Control; 1987 Jan; 8(1):36-40. PubMed ID: 3028975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Profile of a new antibiotic: the combination sulbactam/ampicillin].
    Barba D; Galante D; Esposito S; Giusti G
    Recenti Prog Med; 1987 Jun; 78(6):274-83. PubMed ID: 3310152
    [No Abstract]   [Full Text] [Related]  

  • 59. New β-lactam-β-lactamase inhibitor combinations in clinical development.
    Shlaes DM
    Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sulbactam: a beta-lactamase inhibitor.
    Noguchi JK; Gill MA
    Clin Pharm; 1988 Jan; 7(1):37-51. PubMed ID: 3278833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.